Figure 5
From: Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes
Varying efficacy of epoxytigliane analogues in an in vivo model of melanoma. (A) Kaplan Meier analysis of MM649 melanoma tumors reaching > 100 mm3 in BALB/c Foxn1nu mice following single treatment with vehicle alone (40% PG) or 27 nmole of the indicated epoxytigliane. (B–J) Tumor volumes of MM649 tumors in BALB/c Foxn1nu mice treated with 27 nmole of epoxytigliane analogues. (B) Vehicle only (Vehc.—40% PG), n = 10 tumors; (C) TT (EBC-46), n = 14 tumors; (D) EBC-186, n = 7 tumors; (E) EBC-147, n = 8 tumors; (F) EBC-148, n = 10 tumors; (G) EBC-83, n = 10 tumors; (H) EBC-47, n = 10 tumors; (I) EBC-211, n = 10 tumors; (J) EBC-158, n = 10 tumors.
